Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Ryukaikon Confab Finally Set for November 24; Can Japan Improve Drug Distribution Environment Again?
November 4, 2020
- Working Group Agrees to Designate 10-20 “Stable Supply Medicines” as Top Priority Drugs
November 4, 2020
- Health Minister Stresses Importance of Japan-Made Vaccines Too
November 4, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Clear PAFSC Review
November 2, 2020
- MHLW to Introduce Vaccination Facilitation System for Wholesalers, Medical Institutions
November 2, 2020
- OxyContin Gets Delayed Approval in Japan with Special Distribution Scheme Now in Place
October 30, 2020
- MHLW’s Switch OTC Panel to Take on Mere Advisory Role in Line with Govt’s Policy
October 30, 2020
- Forxiga’s Heart Failure Use Now in Line for November Approval, Covers HFrEF Patients
October 30, 2020
- Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
- Chuikyo Reps Agree on Need to Validate Current Cost-Effectiveness Analysis Scheme
October 29, 2020
- Pharmaceutical Development Council Holds 1st Meeting; Aiming to Sort Out Priority Issues by March
October 29, 2020
- Bill to Amend Immunization Act Submitted to Diet
October 28, 2020
- MHLW Issues Notification on Establishing COVID-19 Vaccination Systems
October 28, 2020
- PM Suga Vows to Work towards Annual Price Revisions: Diet Policy Speech
October 27, 2020
- Reform Minister Asks MHLW to Facilitate Global Launch of Japan-Originated Medical Software Programs
October 27, 2020
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
- MHLW Continues to Collect Info on WHO-Led Study on Veklury
October 26, 2020
- MHLW Wants Distribution Improvement Confab by Year-End, Reckless Discounts Seen with Pricey Meds
October 22, 2020
- Xenograft Library Derived from Japanese Cancer Patients Now Up and Running
October 22, 2020
- No Skipping of Japanese Translation for COVID-19 Vaccine Dossiers: PMDA Official
October 21, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…